Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities
Myron S. Cohen, Ajay Nirula, Mark J. Mulligan, et al.
JAMA (2021) Vol. 326, Iss. 1, pp. 46-46
Open Access | Times Cited: 193

Showing 1-25 of 193 citing articles:

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B. Gilbert, David C. Montefiori, Adrian B. McDermott, et al.
Science (2022) Vol. 375, Iss. 6576, pp. 43-50
Open Access | Times Cited: 1020
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Myron J. Levin, Andrew Ustianowski, Stéphane De Wit, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 23, pp. 2188-2200
Open Access | Times Cited: 614
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Yueh–Ming Loo, Patrick M. McTamney, Rosalinda H. Arends, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 635
Open Access | Times Cited: 191
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
Mounzer Agha, Maggie Blake, Charles Chilleo, et al.
Open Forum Infectious Diseases (2021) Vol. 8, Iss. 7
Open Access | Times Cited: 147
Potential therapeutic options for COVID-19: an update on current evidence
Zahra Niknam, Ameneh Jafari, Ali Golchin, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 136
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
Peter B. Gilbert, David C. Montefiori, Adrian B. McDermott, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 128
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
Vivek Naranbhai, Wilfredo F. García-Beltrán, Christina C. Chang, et al.
The Journal of Infectious Diseases (2021) Vol. 225, Iss. 7, pp. 1141-1150
Open Access | Times Cited: 118
Neutralizing antibodies for the prevention and treatment of COVID-19
Lanying Du, Yang Yang, Xiujuan Zhang
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 10, pp. 2293-2306
Open Access | Times Cited: 117
Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell, Kanika Vanshylla, Timm Weber, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 925-944
Open Access | Times Cited: 117
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 105
Prophylaxis against covid-19: living systematic review and network meta-analysis
Jessica Bartoszko, Reed Siemieniuk, Elena Kum, et al.
BMJ (2021), pp. n949-n949
Open Access | Times Cited: 103
Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
David S. Khoury, Timothy E. Schlub, Deborah Cromer, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 2, pp. 381-388
Open Access | Times Cited: 102
COVID-19 and cellular senescence
Clemens A. Schmitt, Tamar Tchkonia, Laura J. Niedernhofer, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 4, pp. 251-263
Open Access | Times Cited: 101
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
Thomas L Holland, Adit A. Ginde, Roger Paredes, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 10, pp. 972-984
Open Access | Times Cited: 99
SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
Henning Gruell, Kanika Vanshylla, Michael Korenkov, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 9, pp. 1231-1241.e6
Open Access | Times Cited: 71
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
Michael Dougan, Masoud Azizad, Peter Chen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 69
Antiviral neutralizing antibodies: from in vitro to in vivo activity
Dennis R. Burton
Nature reviews. Immunology (2023) Vol. 23, Iss. 11, pp. 720-734
Open Access | Times Cited: 62
Measures to Prevent and Control COVID-19 in Skilled Nursing Facilities
Benjamin E. Canter, Agnė Ulytė, Brian E. McGarry, et al.
JAMA Health Forum (2025) Vol. 6, Iss. 1, pp. e245175-e245175
Open Access | Times Cited: 1
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis
Joanne S. K. Teh, Julien Coussement, Zoe C. F. Neoh, et al.
Blood Advances (2021) Vol. 6, Iss. 7, pp. 2014-2034
Open Access | Times Cited: 70
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
Michael Dougan, Masoud Azizad, Bharat Mocherla, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e440-e449
Open Access | Times Cited: 63
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels
Jens Lundgren, Birgit Grund, Christina E. Barkauskas, et al.
Annals of Internal Medicine (2021) Vol. 175, Iss. 2, pp. 234-243
Open Access | Times Cited: 63
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study
Vivek Naranbhai, Claire A. Pernat, Alexander Gavralidis, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 1, pp. 12-23
Open Access | Times Cited: 61
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Page 1 - Next Page

Scroll to top